D. Hickinson

发表

Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.

Mohammad A. Ghattas, H. Bönisch, C. Dive, 2010, Cancer research.

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

Paul D. Smith, R. Wilkinson, B. Barlaam, 2010, Clinical Cancer Research.

Association of a phosphatidylinositol-specific 3-kinase with a human trans-Golgi network resident protein

C. Downes, S. James, J. Lucocq, 1997, Current Biology.

Role of EGFR but not HER2 or HER3 gene copy number in predicting sensitivity of head and neck squamous cell carcinoma (SCCHN) cell lines to EGFR tyrosine kinase inhibitors

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2007 .

5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase.

Paul D. Johnson, R. Morgentin, R. Bradbury, 2005, Bioorganic & medicinal chemistry letters.

A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.

James S. Scott, B. Barlaam, R. Ducray, 2008, Bioorganic & medicinal chemistry letters.

Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.

James S. Scott, B. Barlaam, R. Bradbury, 2007, Bioorganic & Medicinal Chemistry Letters.

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

N. Carragher, P. Elvin, B. Davies, 2009, Molecular oncology.

Identification of Biomarkers in Human Head and Neck Tumor Cell Lines That Predict For In Vitro Sensitivity to Gefitinib

Marie C. South, F. Hirsch, P. Bunn, 2009, Clinical and translational science.

Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.

S. Barry, A. Ryan, R. Odedra, 2011, International journal of oncology.

265 POSTER A MEK1/2 inhibitor, AZD6244 (ARRY-142886), shows beneficial effects when combined with standards of care or novel therapies – mechanistic characterisation suggests a role for apoptosis

Paul D. Smith, B. Davies, A. Logié, 2008 .

Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.

B. Barlaam, R. Bradbury, P. Ballard, 2013, ACS medicinal chemistry letters.